1. Introduction {#s0005}
===============

Enterobacteriaceae comprises a group of gram negative bacteria that are known to cause several important infections such as urinary tract infections, cystitis, wound sepsis, pneumonia, bacteremia, and meningitis ([@b0095]). Multiple antibiotic resistance, particularly resistance to carbapenem, among Enterobacteriaceae is a major public health concern. Carbapenem-resistant Enterobacteriaceae, reported mostly in hospital-associated infections, is associated with more than 50% mortalities which poses a great challenge in patient care units ([@b0135], [@b0010], [@b0100], [@b0080], [@b0110]). Resistance to carbapenems is attributed to the ability to produce three different categories of carbapenemases; (1) class A (serine carbapenemases, such as *Klebsiella pneumoniae* carbapenemase (KPC)), (2) class B, metallo-β-lactamases, such as IMP, VIM, and NDM, and (3) class D (OXA carbapenemases, such as OXA-23 and OXA-48) ([@b0145], [@b0090]).

The rapid identification of carbapenem resistance organisms is critical not only for the initiation of the proper antimicrobial regimen but also for stopping their spread. Several phenotypic methods are available for detection of carbapenemase enzymes such as; modified Hodge test (MHT), combined disk test (CDT) and inhibitor based *E*-test. However, none of the current phenotypic tests offer optimal sensitivities and specificities. Modified Hodge test (MHT) has been extensively used as a specific method to detect un-typed carbapenemase activity and is currently the only method recommended by the Clinical and Laboratory Standards Institute (CLSI) ([@b0120]). Although MHT is useful for detection of carbapenemases, it has low sensitivity ([@b0055]) and low specificity for metallo-enzymes ([@b0035], [@b0055]). In addition, MHT may produce false positive results mainly due to CTX-M-producing strains with reduced outer membrane permeability and high-level AmpC-producers ([@b0050], [@b0125]). Similarly for the inhibitor-based *E*-test, a test for detection of *K. pneumoniae* carbapenemases (KPC), false-positive test results may occur if AmpC β lactamases are coproduced ([@b0125], [@b0140], [@b0165]).

Thus, phenotypic methods are growth dependent and time-consuming as it takes 18--24 h to completion, not clinically useful and results are also subjective ([@b0035], [@b0055]). Therefore, identification by molecular methods such as real time-PCR have been shown to be sensitive and more accurate for identification of carbapenemase genes. Moreover, diagnosis by molecular methods is comparatively faster than phenotypic assays as the extra overnight incubation step is superfluous. ([@b0075], [@b0070], [@b0150]). The current study was designed to evaluate and compare the sensitivity and specificity of the phenotypic assays, MHT, MicroScan, and *E*-test, with Gene Expert Carba-R assay, as a rapid, low-cost real-time PCR method, for the detection of carbapenemase-producing *K. pneumoniae* and *E. coli* isolates in Riyadh region.

2. Materials and methods {#s0010}
========================

2.1. Bacterial isolates and culture conditions {#s0015}
----------------------------------------------

Sixty non-duplicated isolates were collected from patients admitted to Prince Sultan Military Medical City in Riyadh, Saudi Arabia from 2014 to 2015. Both outpatients and inpatients were included and samples were obtained from urine. Isolates were maintained by routinely culturing on blood agar (BA) plates and MacConkey agar plates for 18--24 h at 37 °C. Identification of the isolates were performed using several assays such as colonial morphology, Oxidase test, API 20E (bioMerieux, Inc) and MicroScan walkaway 96 plus (SIEMENS Healthcare diagnostics). Of the sixty isolates, twenty six were *E. coli* and thirty four were *K. pneumoniae.*

2.2. Phenotypic screening of carbapenemases {#s0020}
-------------------------------------------

### 2.2.1. Antimicrobial susceptibility tests by MicroScan system {#s0025}

Resistance to and MIC values of 14 antibiotics including imipenem, meropenem, ertapenem were determined by MicroScan walkaway 96 plus (SIEMENS Healthcare diagnostics) as described by manufacturer's instructions. Briefly, 0.5 McFarland bacterial suspension from each isolate was prepared and transferred to the gram negative bacteria panel (Neg panel Type 49). Following 18--24 h incubation, MIC values were obtained and analyzed according to the standard Clinical and Laboratory Standards Institute, 2014 guidelines (CLSI). Isolates that were resistant to imipenem, meropenem or ertapenem were considered carbapenem-resistant.

### 2.2.2. Modified Hodge test (MHT) {#s0030}

The ability of carbapenem-resistant isolates to produce carbapenemases was investigated by MHT technique. Briefly, 0.5 McFarland suspension of carbapenem susceptible strain *E. coli* ATCC 25922 was streaked as a lawn over Mueller Hinton agar (MHA) plates and disks loaded with meropenem (10 μg) or ertapenem were placed in the center of the test area. Isolates to be tested along with a positive control (*K. pneumoniae* ATCC1705) and negative control (*K. pneumoniae* ATCC1706) were streaked as straight lines from the edge of the meropenem disk to the edge of the plate. Inoculated plates were allowed to dry for 15 min at room temperature and incubated overnight at 35 ± 2 °C for 16--24 h. The test was considered positive when a clover leaf-like shape was observed.

2.3. Molecular Xpert® Carba-R assay {#s0035}
-----------------------------------

Xpert® Carba-R (Cepheid, Sunnyvale, USA) is a fully automated and integrated system for sample preparation, DNA extraction, amplification and qualitative detection of target genes using multiplex real time PCR assays. This new assay involves a single-use disposable cartridge that holds PCR reagents and hosts the PCR processes. The cartridge contains primers that target and amplify a number of carbapenemase resistance genes; bla~IMP~, bla~VIM~, bla~NDM~, bla~KPC~, and bla~OXA-48~. Xpert Carba-R assay kit contains sufficient reagents to process 10 samples. In addition, it contains a positive control which carries all the 5 beta-lactamase gene sequences detected and negative control with no beta-lactamase gene sequences. Isolates to be tested were inoculated into the sample reagent and loaded into the cartridge as described by manufacturers' instructions. Results were analyzed using GeneXpert Software Version 4.3.

3. Results {#s0040}
==========

3.1. Antibiotic susceptibility of *E. coli* and *K. pneumoniae* {#s0045}
---------------------------------------------------------------

MicroScan antibiotic susceptibility profile of the 60 clinical isolates revealed that *E. coli* and *K. pneumoniae* have different susceptibilities where 24 (40%) isolates of *K. pneumoniae* and only 3 (5%) isolates of *E. coli* were resistant to imipenem, meropenem and ertapenem ([Table 1](#t0005){ref-type="table"}). Of the 26 *E. coli* isolates, 3 (11.5%), 2 (7.69%), and 3 (12%) were resistant to imipenem, meropenem and ertapenem, respectively, while 22 (84.6%), 24 (92.3%) and 23 (88%) were sensitive to imipenem, meropenem and ertapenem, respectively. Only one (4%) isolate exhibited intermediate susceptibility to imipenem. For the 34 *K. pneumoniae* isolates, 11 (32%), 12 (35%), and 24 (70.58%) were resistant to imipenem, meropenem and ertapenem, respectively, while 17 (50%), 20 (59%) and 10 (29.4%) were sensitive to imipenem, meropenem and ertapenem, respectively ([Fig. 1](#f0005){ref-type="fig"}). Only 2 (6%) and 6 (18%) isolates exhibited intermediate susceptibility to meropenem and imipenem, respectively. Interestingly, these isolates have high resistance values against other antibiotics as indicated from MICs. Five (19%) out of 26 *E. coli* isolates and 19 (52.7) out of 36 *K. pneumoniae* were defined as multi drug resistant isolates. Of the 60 isolates only 2 (3.3%) were resistant to all the tested antibiotics except Amikacin and only two were sensitive to all antibiotics. Five (14.7%) of *K. pneumoniae* isolates were resistant to all tested antibiotics but exhibited intermediate susceptibility to Amikacin. Only one *E. coli* isolate was sensitive to all antibiotics except for Ampicillin.

3.2. Carbapenem resistant isolates produce carbapenemase {#s0050}
--------------------------------------------------------

The ability of *E. coli* and *K. pneumoniae* isolates to produce carbapenemases was tested using MHT. Out of the 60 isolates, 26 (43%) were positive for carbapenemase production. Of these, 23 (67.6%) out of 34 isolates were positive for *K. pneumoniae* and only 4 out of 26 were positive for *E. coli* ([Table 2](#t0010){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}).

3.3. Rapid identification of carbapenem genes using Gene Xpert Carba-R assay {#s0055}
----------------------------------------------------------------------------

A total of 60 isolates were tested by the Xpert Carba-R Assay for the target carbapenem-resistant gene sequences (bla~IMP~, bla~VIM~, bla~NDM~, bla~KPC~, and bla~OXA-48~). The results were interpreted by the Gene-Xpert software from measured fluorescent signals and embedded calculation algorithms ([Fig. 3](#f0015){ref-type="fig"}). PCR results indicated that 29 (48.3%) out of 60 isolates were positive for carbapenem resistance determine genes. As shown in [Table 5](#t0025){ref-type="table"}, OXA-48 gene was the most frequent where it was detected in 23 (38.33%) isolates, (1 (4%) isolate of *E. coli*, and 22 (64.7%) isolates of *K. pneumoniae*), followed by NDM in 4 (6.6%) isolates (2 (8%) in *E. coli* and 2 (5.8%) in *K. pneumoniae* isolates), VIM was detected only in one isolate of *K. pneumoniae* (2.9%). KPC and IMP-1 genes were not detected in any of the tested isolates.

3.4. Rapidity, sensitivity and specificity of Xpert Carba-R assay in comparison with phenotypic tests {#s0060}
-----------------------------------------------------------------------------------------------------

The results showed a notable variation between phenotypic assays, MicroScan and MHT, and molecular-based Xpert Carba-R PCR assay in terms of rapidity, sensitivity and specificity. The specificity of MicroScan was 100% while its sensitivity to ETP, IMP, and MER was 93%, 68.9%, and 55.17%, respectively. For the modified Hodge test, the specificity was 96.77% and sensitivity was 89.65%. Although some results of phenotypic assays matched with the definite PCR identification, some results were misleading. Out of the 29 positive PCR samples (i.e. carbapenem resistant), three samples of *K. pneumoniae* (samples; 1, 7, and 8) were negative for the MHT and one *E. coli* sample was MHT positive but negative for the PCR. For the MicroScan results, 9 samples (8 for *K. pneumoniae* and 1 for *E. coli*) were determined as carbapenem sensitive for (Imipenem and Meropenem). These 9 samples were determined as carbapenem resistance by PCR ([Table 5](#t0025){ref-type="table"}). Another important item that should be considered is the time factor. In the phenotypic assays where MicroScan takes 18--24 h and MHT 16-24 h, PCR takes less than an hour. From the above findings, PCR is rapid, accurate and sensitive assay for detection of carbapenem-resistant Enterobacteriaceae.

4. Discussion {#s0065}
=============

Enterobacteriaceae members such as *E. coli* and *K. pneumoniae* are among the most important causative agents of hospital-acquired and community-onset infections of human beings ([@b0130]). Carbapenemases production by these bacteria is associated with therapy failures, dissemination, and increased mortality rates ([@b0105]). Therefore, reliable detection methods with rapidity, high sensitivity and specificity is required ([@b0110]). The rapid identification of carbapenem resistance bacteria allows physicians not only to describe the proper antimicrobial regimen but also to restrict their spreading. The preliminary screening for carbapenemase producers in clinical specimens is based first on phenotypic tests, whereas, confirmation tests are mainly based on molecular assays. However, traditional phenotypic methods have some disadvantages such as; are time-consuming, difficult to interpret, and the sensitivity/specificity vary between different species ([@b0105], [@b0090], [@b0030], [@b0170]).

The phenotypic assays, MHT has been suggested as the gold standard technique to detect carbapenemase producing bacteria in the past years ([@b0115]). Of the 60 isolates tested in the current study, 27 (45%) were MHT positive ([Table 2](#t0010){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}). Our results showed that MHT failed to detect one isolate of *K. pneumoniae* which was PCR positive for NDM gene. As well, two *K. pneumoniae* isolates were OXA-48 producers but were negative for MHT ([Table 5](#t0025){ref-type="table"}). The overall sensitivity and specificity of the MHT were 89.6% and 96.77%, respectively. Doyle et al., found that the sensitivity and specificity for MHT was 61% and 93%, respectively ([@b0040]). MHT is less reliable to detect NDMs, VIMs, and IMPs producing bacteria; however, it may be useful for detecting KPC and OXA-48 producers ([@b0105], [@b0020], [@b0040]).

Resistance to carbapenem agents is due to carbapenemase and presence of other resistance mechanisms, such as ESBLs, porin mutations and/or presence of efflux pumps ([@b0025]). In our study, carbapenem resistance rates among *K. pneumoniae* isolates were 24 (70.5%), and 5 (19.2%) among *E. coli* isolates, while we found 36 isolates sensitive suggesting resistance mechanism other than carbapenemase production ([@b0150]).

Most carbapenem resistant isolates had high resistance rates against other antibiotics including amikacin, augmentin, ampicillin, cefepime, cefotaxime, ceftazidime, ciprofloxacin, cefuroxime, gentamicin, piperacillin/tazobactam, and trimethoprim/ sulfamethoxazole ([Table 1](#t0005){ref-type="table"}). The resistance rates for carbapenem resistant *K. pneumoniae* isolates were 45.8%, 100%, 100%, 83.3%, 87.7%, 87.7%, 95.8%, 75%, 95.8% and 62.5% respectively, while resistance rates for 5 isolates of carbapenem resistant *E. coli* were 0%, 60%, 100%, 100%, 100%, 100%, 100%, 100%, 40%, 40%, 40% respectively.

Current study found that two isolates of *K. pneumoniae* harbored OXA-48 gene exhibited sensitivity to IMI, MER and ERT antibiotics by Microscan ([Table 1](#t0005){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}). As well, seven isolates of *K. pneumoniae* produced OXA-48 gene and seemed resistant only to ertapenem. For *E. coli* isolates, one OXA-48 producer isolate exhibited resistance to ertapenem but not for IMI or MER ([Table 1](#t0005){ref-type="table"}, [Table 5](#t0025){ref-type="table"}). Several studies had reported that automated susceptibility systems incorrectly labeled up to 87% of carbapenemase-producing *K. pneumoniae* isolates as susceptible to imipenem ([@b0160]). Ertapenem resistance seems to be a marker for carbapenemase production when automated testing methods are used ([@b0160], [@b0005]). This necessitates further testing by phenotypic and genotypic methods. If resources are limited, an elevated MIC for ertapenem could be used as a screening method to determine which isolates need further testing ([@b0160], [@b0005]).

Xpert Carba-R PCR assay can differentiate the most prevalent carbapenemase genes including KPC, NDM, VIM, OXA-48 and IMP-1 in less than an hour. [@b0155]; showed that the sensitivity and specificity of Xpert MDRO for detecting KPC or VIM were 100% and 99.0%, respectively ([@b0155]). Other study evaluated the performance of three commercial molecular assays for detecting major families of carbapenemases; they found that the sensitivity and specificity of Xpert Carba-R kit is 71--100% and 100% for different carbapenemase families ([@b0045]).

However, our study revealed high prevalence of OXA-48 type carbapenemase-producing in 24 (38.33%) isolates, followed by NDM type in 5 isolates, VIM was found less detected only in one isolate of *K. pneumoniae* ([Table 3](#t0015){ref-type="table"} and [Fig. 3](#f0015){ref-type="fig"}). The absence of VIM-1, KPC and IMP genes suggest that these isolates are not major sources of carbapenemases in the Kingdom ([Table 4](#t0020){ref-type="table"}). [@b0175]; found that the most common carbapenemases were of the OXA-48 and NDM respectively. Other studies showed that the OXA-type carbapenemases is a growing problem and the most important reason for resistance to IMI and MER *Acinetobacter's* worldwide ([@b0060], [@b0015], [@b0065]). Other studies performed in Saudi Arabia indicated that OXA-48 and NDM-1 types are the dominant carbapenemases among the Enterobacteriaceae ([@b0085]). The emergence of OXA-48 and NDM carbapenemases among the Enterobacteriaceae in Saudi Arabia may reflect the extensive population flows between the Kingdom, other part of the Middle East, and North Africa where OXA-48 is widespread and the Indian subcontinent where NDM are common ([@b0105]).

Thus awareness of carpbapenemase producing Enterobacteriaceae in Gulf cooperation council countries has important implications for controlling the spread of carpbapenemase producing Enterobacteriaceae in the Middle East and in hospitals accommodating patients transferred from the region ([@b0175]). Thus after we evaluated phenotypic and molecular tests, we recommend using molecular tests such Gene Expert R assay for optimal carbapenemnase detection and it is important to know the type of carbapenemase gene present, reducing material, manpower and cost ([@b0040]), besides recommendation for an initial screening for Enterobacteriaceae by using ertapenem in addition to meropenem and imipenem.
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![Antibiotic resistance profile of the 60 isolates of *E. coli and K. pneumoniae* as determined by MicroScan. (R = resistant, I = intermediate, S = sensitive).](gr1){#f0005}

![Example of *E. coli* isolates showing a positive and negative results with MHT on Muller Hinton Agar. Symbols; (1) *K. pneumoniae* negative control ATCC 1706. (2) *E. coli* 25922. (3) Meropenem disk. (4) *K. pneumoniae* positive control ATCC1705. (5) Negative MHT result. (6) Positive MHT result.](gr2){#f0010}

![Gene Xperts Carba-R assay analysis. (A) OXA-48 gene detected in *K. pneumoniae* isolates, (B) NDM gene detected in *E. coli* isolates, (C) VIM gene detected in *K. pneumoniae* isolates, and (D) positive control KPC of *K. pneumoniae.*](gr3){#f0015}

###### 

Overall rates of antibiotics susceptibility test of *E. coli* (*n* = 26) and *K. pneumoniae isolates* (*n* = 34) as determined by MicroScan.

  Antibiotics     R[⁎](#tblfn1){ref-type="table-fn"}*n* (%)   I[⁎](#tblfn1){ref-type="table-fn"}*n* (%)   S[⁎](#tblfn1){ref-type="table-fn"}*n* (%)   ESBL[⁎](#tblfn1){ref-type="table-fn"}*n* (%)                                       
  --------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- ---------------------------------------------- ----------- ----------- ----------- -----------
  Ertapenem       3 (11.5)                                    24 (70.5)                                   0                                           0                                              23 (88.4)   10 (29.4)   0           0
  Imipenem        3 (11.5)                                    11 (32.3)                                   1 (3.8)                                     6 (17.6)                                       22 (84.6)   17 (50)     0           0
  Meropenem       2 (7.6)                                     12 (35.2)                                   0                                           2 (5.8)                                        24 (92.3)   20 (58.8)   0           0
  Amikacin        2 (7.6)                                     12 (35.2)                                   0                                           10 (29.4)                                      24 (92.3)   12 (35.2)   0           0
  Amox/kclav      9 (3.6)                                     29 (85.8)                                   5 (19)                                      2 (5.8)                                        12 (46.1)   3 (8.8)     0           0
  Ampicillin      25 (96)                                     33 (97)                                     0                                           0                                              1 (3.8)     1 (2.9)     0           0
  Cefepime        25 (96)                                     27 (79)                                     0                                           1 (2.9)                                        1 (3.8)     6 (17.6)    0           0
  Cefotaxime      4 (15.3)                                    17 (50)                                     0                                           0                                              1 (3.8)     6 (17.6)    21 (80.7)   11 (32.3)
  Ceftazidime     4 (15.3)                                    16 (47)                                     0                                           0                                              1 (3.8)     6 (17.6)    21 (80.7)   12 (35.2)
  Cefuroxime      25 (96)                                     32 (94)                                     0                                           0                                              1 (3.8)     2 (5.8)     0           0
  Ciprofloxacin   15 (57.6)                                   29 (85)                                     0                                           0                                              11 (42.3)   5 (14.7)    0           0
  Gentamicin      15 (57.6)                                   23 (67.6)                                   1 (3.8)                                     0                                              10 (38.4)   11 (32.3)   0           0
  PipTzo          6 (23)                                      27 (79)                                     1 (3.8)                                     1 (2.9)                                        19 (73)     6 (17.6)    0           0
  TrimethSulfa    16 (61.5)                                   18 (53.9)                                   0                                           0                                              10 (41.2)   16 (47)     0           0

(S = sensitive, R = resistant, I = intermediate, ESBL = Extended spectrum beta-lactamase).

###### 

Modified Hodge test results of isolates (*n* = 60).

                               Number of isolates (%)   
  ---------------------------- ------------------------ ------------
  *K. pneumoniae* (*n* = 34)   23 (38.3%)               11 (18.3%)
  *E. coli* (*n* = 26)         4 (6.6%)                 22 (36.6%)
                                                        
  Total (*n* = 60)             27 (45%)                 33 (55%)

###### 

Gene Xperts Carba-R results in all isolates (*n* = 60).

  No.   KPC   NDM   VIM   OXA-48   IMP-1   No.   KPC   NDM   VIM   OXA-48   IMP-1   NO.   KPC   NDM   VIM   OXA-48   IMP-1
  ----- ----- ----- ----- -------- ------- ----- ----- ----- ----- -------- ------- ----- ----- ----- ----- -------- -------
  1     −ve   +ve   −ve   −ve      −ve     21    −ve   −ve   −ve   −ve      −ve     41    −ve   −ve   −ve   −ve      −ve
  2     −ve   −ve   −ve   +ve      −ve     22    −ve   −ve   −ve   −ve      −ve     42    −ve   −ve   −ve   −ve      −ve
  3     −ve   −ve   −ve   +ve      −ve     23    −ve   −ve   −ve   −ve      −ve     43    −ve   −ve   −ve   +ve      −ve
  4     −ve   −ve   −ve   +ve      −ve     24    −ve   −ve   −ve   −ve      −ve     44    −ve   −ve   −ve   −ve      −ve
  5     −ve   +ve   −ve   −ve      −ve     25    −ve   −ve   −ve   −ve      −ve     45    −ve   −ve   −ve   −ve      −ve
  6     −ve   −ve   −ve   −ve      −ve     26    −ve   −ve   −ve   −ve      −ve     46    −ve   −ve   −ve   −ve      −ve
  7     −ve   −ve   −ve   +ve      −ve     27    −ve   −ve   −ve   −ve      −ve     47    −ve   −ve   −ve   −ve      −ve
  8     −ve   −ve   −ve   +ve      −ve     28    −ve   −ve   −ve   −ve      −ve     48    −ve   −ve   −ve   +ve      −ve
  9     −ve   −ve   −ve   +ve      −ve     29    −ve   −ve   −ve   −ve      −ve     49    −ve   −ve   −ve   +ve      −ve
  10    −ve   +ve   −ve   −ve      −ve     30    −ve   −ve   −ve   −ve      −ve     50    −ve   −ve   −ve   +ve      −ve
  11    −ve   −ve   −ve   +ve      −ve     31    −ve   −ve   −ve   −ve      −ve     51    −ve   −ve   −ve   +ve      −ve
  12    −ve   −ve   −ve   +ve      −ve     32    −ve   −ve   −ve   −ve      −ve     52    −ve   −ve   −ve   +ve      −ve
  13    −ve   −ve   +ve   −ve      −ve     33    −ve   −ve   −ve   −ve      −ve     53    −ve   −ve   −ve   +ve      −ve
  14    −ve   −ve   −ve   +ve      −ve     34    −ve   −ve   −ve   −ve      −ve     54    −ve   −ve   −ve   −ve      −ve
  15    −ve   −ve   −ve   +ve      −ve     35    −ve   +ve   −ve   −ve      −ve     55    −ve   −ve   −ve   −ve      −ve
  16    −ve   −ve   −ve   +ve      −ve     36    −ve   +ve   −ve   −ve      −ve     56    −ve   −ve   −ve   +ve      −ve
  17    −ve   −ve   −ve   +ve      −ve     37    −ve   −ve   −ve   +ve      −ve     57    −ve   −ve   −ve   +ve      −ve
  18    −ve   −ve   −ve   +ve      −ve     38    −ve   −ve   −ve   −ve      −ve     58    −ve   −ve   −ve   +ve      −ve
  19    −ve   −ve   −ve   −ve      −ve     39    −ve   −ve   −ve   −ve      −ve     59    −ve   −ve   −ve   −ve      −ve
  20    −ve   −ve   −ve   −ve      −ve     40    −ve   −ve   −ve   −ve      −ve     60    −ve   −ve   −ve   −ve      −ve

Samples number; 1--16, 18, 21, 26, 31, 36--38, 40, 45--51, 54--56 are for *K. pneumoniae* and samples number; 17, 19, 20, 22, 23--25, 27--30, 32--35, 39, 41--44, 52, 53, 57--60 are for *E. coli*.

###### 

Prevalence of carbapenem resistance determining genes among all isolates (*n* = 60).

  Carbapenem resistance genes   No. of total isolates   Percentage (%)
  ----------------------------- ----------------------- ----------------
  OXA-48                        23                      38.33%
  NDM                           4                       6.66%
  VIM                           1                       1.66%
  KPC                           --                      --
  IMP                           --                      --

###### 

Comparison between phenotypic assays (MicroScan and MHT) and Xpert Carba-R molecular assay.

  Strain No.   Species           MHT   MicroScan   Xpert Carba-R                       
  ------------ ----------------- ----- ----------- --------------- --- ----- --- ----- --------
  1            *K. pneumoniae*   −ve   S           ⩽0.25           S   ⩽1    S   ⩽1    OXA-48
  3            *K. pneumoniae*   +ve   R           2               S   ⩽1    R   ⩽1    OXA-48
  5            *K. pneumoniae*   +ve   R           2               S   ⩽1    S   ⩽1    OXA-48
  6            *K. pneumoniae*   +ve   R           2               S   ⩽1    S   ⩽1    OXA-48
  7            *K. pneumoniae*   −ve   S           0.5             S   ⩽1    S   ⩽1    OXA-48
  8            *K. pneumoniae*   −ve   R           \>1             R   \>8   R   \>8   NDM
  9            *K. pneumoniae*   +ve   R           \>1             I   2     S   ⩽1    OXA-48
  15           *K. pneumoniae*   +ve   R           \>1             S   ⩽1    S   \<1   OXA-48
  30           *E. coli*         +ve   S           ⩽0.25           S   ⩽1    S   ⩽1    -ve
  41           *E. coli*         +ve   R           2               S   2     S   ⩽1    OXA-48
  47           *K. pneumoniae*   +ve   R           \>1             S   ⩽1    S   ⩽1    OXA-48
  48           *K. pneumoniae*   +ve   R           4               S   ⩽1    S   ⩽1    OXA-48
  56           *K. pneumoniae*   +ve   R           \>1             S   \<1   S   \<1   OXA-48
